Respected Member Institutions
External Partners Under NDA
1 to Many
We Connect Clinicians, Researchers, VCs, Industry Personnel, and Government Agencies
Joseph Loscalzo, M.D., PH.D.Program Director
Dr. Loscalzo is the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, and Chairman of the Department of Medicine and Physician-in-Chief at Brigham and Women’s Hospital. He is a summa cum laude graduate of the University of Pennsylvania, where he also obtained his MD and PhD. in biochemistry in 1978. He trained in internal medicine and cardiology at Brigham and Women’s Hospital, after which he was appointed to the hospital staff and Harvard Medical School faculty. In 1994 Dr. Loscalzo moved to Boston University, first as Chief of Cardiology, and, in February of 1997, Chair of Medicine. In July, 2005, he returned to the Harvard faculty in his current role. He has authored more than 700 articles, 36 books, and 31 patents for his work in the field of vascular biology. He is a member of the American Society of Clinical Investigation, the Association of American Physicians, the Institute of Medicine of the National Academy of Sciences, and the American Academy of Arts and Sciences. Currently he is a senior editor of Harrison’s Principles of Internal Medicine and Editor-in-Chief of Circulation.
David E. Golan, M.D., PH.D.Program Director
Dr. Golan, MD, PhD became the first Dean for Graduate Education at Harvard Medical School (HMS) in November 2008. He is a professor in the HMS Department of Biological Chemistry and Molecular Pharmacology, where his laboratory applies biophysical and cell-imaging methodologies to the study of membrane-targeted proteins in blood cells and in the vascular endothelium. He is also the George R. Minot Professor of Medicine at HMS and Physician in the Department of Medicine at Brigham and Women’s Hospital (BWH) and the Dana-Farber Cancer Institute. He is a founding Scholar of the Academy at Harvard Medical School. After earning his AB summa cum laude in chemistry at Harvard College, Dr. Golan received his PhD in molecular biophysics and biochemistry and his MD from Yale University, followed by clinical training in internal medicine and hematology at BWH. Dr. Golan founded and directed the core course in pharmacology in the New Pathway curriculum at HMS from 1989 to 2006. He currently co-directs a translational pharmacology course in the Therapeutics Graduate Program, the Leder Human Biology and Translational Medicine Graduate Program, and the Master’s Program in Clinical and Translational Investigation at HMS. These courses’ guiding principle is that drug mechanisms are best understood in the context of the physiological, biochemical, and pathophysiological pathways on which the drugs act. He also chairs the HMS Division of Medical Sciences, directs the Harvard Therapeutics Graduate Program, and coordinates the design, development, implementation, and oversight of the master’s degree programs at HMS.
John Parrish, M.D.Program Director
Dr. Parrish is Distinguished Professor of Dermatology at Harvard Medical School. He is the Founder and CEO of the Consortia for Improving Medicine with Innovation and Technology (CIMIT), a 15-year-old collaboration among 13 Boston-based and 4 international academic, medical and engineering institutions to develop and adopt targeted medical devices and technologies. CIMIT supports the infrastructure of B-BIC. For two decades, Dr. Parrish served as chief of the Department of Dermatology at Massachusetts General Hospital, founding the MGH Wellman Center for Photomedicine, the first – and now the world’s largest – multidisciplinary research group to study the effects of light and lasers on tissue. A graduate of Duke University and Yale University School of Medicine, Dr. Parrish is a member of the Institute of Medicine, National Academy of Science, and the American Academy of Arts and Sciences. Dr. Parrsh is the author or co-author or more than 300 publications, including eight books.
Elliott Antman, M.D.Director, Skills Development Center
Dr. Elliott Antman is Professor of Medicine and Associate Dean for Clinical/Translational Research at Harvard Medical School and a senior physician in the Cardiovascular Division of the Brigham and Women’s Hospital in Boston, Massachusetts. As Senior Investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, his ongoing research studies help refine diagnostic and therapeutic modalities in routine clinical use today, including cardiac specific troponins and novel antithrombotic agents. Dr. Antman participates actively in American Heart Association (AHA) activities, locally, nationally, and internationally. He was the Chairman of the joint ACC/AHA Task Force on Practice Guidelines from January 2003 through December 2005, and has chaired or been a member of several guidelines committees. Dr. Antman is a member of the AHA Science and Advisory Coordinating Committee, was on the Manuscript Oversight Committee, and Chaired the Committee on Scientific Sessions Program from 2011-2012. He currently chairs the AHA Advocacy Coordinating Committee. He is the recipient of the Meritorious Achievement Award from the AHA (2006) and was the recipient of the Herrick Award of the Council on Clinical Cardiology in 2010. Dr. Antman will be the President of the American Heart Association for 2014-2015.
Elazer Edelman, M.D., PH.D.Associate Director
Dr. Elazer Edelman is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of Medicine at Harvard Medical School, and a coronary care unit cardiologist at the Brigham and Women’s Hospital in Boston. He and his laboratory have pioneered basic findings in vascular biology and the development and assessment of biotechnology. Dr. Edelman directs the Harvard-MIT Biomedical Engineering Center (BMEC), dedicated to applying the rigors of the physical sciences to elucidate fundamental biologic processes and mechanisms of disease. BMEC programs span a wide range of disciplines, with its resources made available to investigators from MIT and Harvard. Edelman holds a diploma from, and is a fellow of, the American College of Cardiology, the American Heart Association, the American Institute for Medical and Biological Engineering, and the American Society for Clinical Investigation. He is also a fellow of the Institute of Medicine of the National Academy of Science, the National Academy of Engineering and the National Academy of Inventors. As Chief Scientific Advisor of Science: Translational Medicine, he has set the tone for the national debate on translational research and innovation.
Mason Freeman, M.D.Associate Director
Professor of Medicine, Harvard Medical School. In 1985 he founded the Lipid Clinic at MGH and began to investigate the use of the first HMG CoA reductase inhibitor, lovastatin, in patients with genetic hyperlipidemias, prior to FDA approval of that drug. He leads a pre-clinical and clinical investigative team that has pioneered a novel model of academia-based, commercial drug development and its first program, involving the generation of a novel oral anti-diabetic drug, that is now entering phase 3 clinical trials.
Roger Kitterman, MBAExecutive Director
Roger Kitterman is the Executive Director of the Boston Biomedical Innovation Center and the Managing Partner of the Partners Innovation Fund. The Partners Innovation Fund, established in 2007, was launched with a total commitment of $35 million from Brigham and Women’s Hospital and Massachusetts General Hospital. It addresses Partners HealthCare’s unmet need for funding of its early-stage technologies to drive improved medical care for patients. Roger is an experienced venture capital investor with 20 years in the industry and has guided multiple venture-backed companies through the earliest stages of development. He has also been the startup CEO for three venture-backed companies and is a founder of Mass Medical Angels, the only life-science focused angel investment group in Boston. Previously, he was a general partner at Mi3 Venture Partners, an early-stage bioengineering-focused fund. Prior to joining Mi3, he was a managing director at Lee Munder Venture Partners, the venture capital arm of Lee Munder Capital Group. He joined Lee Munder from Boston University’s venture fund, where he made venture capital investments in the life sciences and developed and managed spinouts from the university and Boston Medical Center. Roger began his venture capital career in Eastern Europe with the Bulgarian-American Enterprise Fund, a $55 million venture capital fund.
Steven Schachter, M.D.Associate Director
Steven Schachter is Professor of Neurology at Harvard Medical School; Chief Academic Officer and Director of NeuroTechnology for the Center for Integration of Medicine and Innovative Technology, Boston; and Senior Neurologist, Beth Israel Deaconess Medical Center, Boston. Dr. Schachter is Co-Chair of the ILAE Therapeutics Strategies Commission and serves on the ILAE Global Campaign Task Force. He is Past President of the American Epilepsy Society, past Chair of the Professional Advisory Board of the Epilepsy Foundation and a member of the Epilepsy Foundation Board of Directors. He has directed over 70 research projects involving antiepileptic therapies, and published over 200 articles and chapters. He compiled the 6-volume Brainstorms series, which has been distributed to over 150,000 patients and families worldwide, and edited or written 23 other books on epilepsy and behavior. Dr. Schachter is the founding editor and editor-inchief of Epilepsy & Behavior.
Rosemarie Cannistraro Project Coordinator
Rosemarie is the Project Coordinator for the Office of the Chairman, Department of Medicine – Dr. Joseph Loscalzo at Brigham and Women’s Hospital. She has been providing Executive level support and assistance in various roles at BWH for the past 16 years; first in the Department of Medicine, Cardiovascular Division, and then in the offices of the Chief Operating Officer, Chief Executive Officer and most recently for the Chief Nursing Officer. Prior to joining Brigham and Women’s Hospital, she served as a Practice Manager for a private Obstetrics & Gynecology practice for 18 years.
Erica Kates, M.A., CRAGrants Administrator
Erica Kates has worked in Research Administration since 2002, and has been the financial manager and administrator for the Loscalzo Lab since 2012. She is a Certified Research Administrator, and also worked for many years as an academic grants researcher and as a professional biomedical science editor.
Erin McKenna, MBADeputy Director
Erin is the Senior Project Manager for the Boston Biomedical Innovation Center (B-BIC). Erin brings to B-BIC over sixteen years of medical device product development and commercialization. She started her career in Research and Development at Boston Scientific, and launched several vascular graft and peripheral embolization products before shifting her focus to identifying and implementing company-wide product development lifecycle process improvements. Ms. McKenna holds MBA and MS degrees in Global Management from Babson College and a bachelor’s degree in Chemical Engineering from Stevens Institute of Technology.
Rachel Napear Director, Marketing & Communications
Rachel currently leads the Boston Biomedical Innovation Center’s Marketing & Communications program, overseeing branding, communications, content, and events. She also works closely with portfolio companies to provide both strategic and tactical communications & marketing counsel.
Rachel joined B-BIC in 2016 after running her own strategic-communications practice providing marketing, communications, and media-related services to businesses, politicians and issue advocacy groups. In addition, Rachel worked as an adjunct professor in Entrepreneurship & Marketing at Rutgers Executive MBA program in the United States and China. Prior to that Rachel worked for many years as a political consultant, managing campaigns across the country and training advocacy groups in communications best practices around the world.
John Randle, PH.D.Coach - Therapeutic Technologies
John Randle is Principal at Random Walk Ventures, LLC. He is a pharmaceutical discovery & development consultant with over 25 years’ experience at all stages from target and lead selection through to product life cycle management, notably at Vertex Pharmaceuticals, CombinatoRx, Inc. and Annovation Biopharma. He received his Ph.D. at McGill University and began his career at Servier and Rhône-Poulenc Rorer, before moving to Boston.
Paul Tessier Coach - Device Technologies
Paul Tessier is a Member of the CIMIT Accelerator Team and an experienced medical device developer, manager, and entrepreneur. He oversaw the development of many successful medical products at Hewlett-Packard and Philips Medical Systems prior to founding a series of companies: Radianse, Inc which provided unique workflow solutions for healthcare; Technology Innovators which supplied technology to assist the elderly and infirm; and Pure Marrow an early stage start-up focused on transforming stem cell and marrow harvesting.
Lesley Watts Director, Operations and Finance
Lesley Watts is the Operations and Finance Director for the Boston Biomedical Innovation Center (B-BIC). With more than twenty years of experience in research management, Lesley specializes in supporting multi-institutional, multi-disciplinary collaborations. She started her career as part of the team responsible for re-organizing the Eastern Cooperative Oncology Group, one of the National Cancer Institute’s cooperative clinical trials groups. She later became the Administrative Director of the National Center for Research Resources’ General Clinical Research Center at Brigham and Women’s Hospital. Before joining B-BIC, she was the Senior Program Manager at the Center for Integration of Medicine & Innovative Technology. Lesley holds a Masters in Policy, Planning, and Administration from Boston College and a bachelor’s degree in Political Science and Economics from McGill University.
Elisabeth Battinelli, M.D.Brigham and Women’s Hospital
Dr. Battinelli is an Assistant Professor of Medicine at Harvard Medical School and an Associate Physician at Brigham and Women’s Hospital in the Division of Hematology. Dr. Battinelli splits her time between clinical and research responsibilities. She has a specialty clinic that cares for patients with platelet, hemostasis, and thrombotic disorders and also works closely with the Pathology Department in interpreting coagulation testing. In addition, she has a research laboratory that focuses on understanding the interaction between platelets and cancer cells and how regulation of platelet function can inhibit metastasis.
Nancy Berliner, M.D.Brigham and Women’s Hospital
Chief, Division of Hematology and Professor of Medicine, Harvard Medical School. Her research spans the fields of both benign and malignant hematologic disorders. She is Deputy Editor for Blood, and a member of the Institute of Medicine.
John Brownstein, PH.D.Boston Children’s Hospital
Dr. Brownstein is an Associate Professor at the Harvard Medical School and a faculty member of the Children’s Hospital Informatics Program at Harvard-MIT Division of Health Sciences and Technology. Dr. Brownstein works on new statistical modeling and medical informatics approaches for accelerating the translation of public health surveillance research into practice.
Benjamin Ebert, M.D., PH.D.Brigham and Women’s Hospital
Benjamin Ebert is an Associate Professor of Medicine at Harvard Medical School, an Institute Member of the Broad Institute, Leader of the Leukemia Program for the Dana-Farber/Harvard Cancer Center, and co-Director of the Cancer Program at the Harvard Stem Cell Institute. He received a bachelor’s degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an M.D. from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute. The Ebert laboratory has a long-standing interest in the genetic lesions that drive myeloid malignancies and the clinical and biological consequences of specific mutations.
Farouc Jaffer, M.D., PH.D.Massachusetts General Hospital
Farouc Jaffer is an Associate Professor of Medicine at Harvard Medical School. In 2013, he was elected to the American Society of Clinical Investigation (ASCI). He is the Director of Vascular Imaging at the Cardiovascular Molecular Imaging Program. His lab is interested in applying molecular imaging technology to 1) understand the evolution and therapy of inflammation in atherosclerosis though serial, high-resolution imaging and 2) develop translatable, catheter-based fluorescence technology to study vascular disease in human coronary sized arteries.
Bruce D. Levy, M.D.Brigham and Women's Hospital
Dr. Levy is the Parker B. Francis Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital and chief of the Division of Pulmonary and Critical Care Medicine. His research focuses on the roles of endogenous counter-regulatory mediators in the lung, and his lab’s mission is to identify novel pathways and cellular targets that promote resolution of pulmonary inflammation or injury and to translate these findings to develop a better understanding of physiology and the pathogenesis of lung disease. His work is helping to establish naturally-derived small molecules as templates for rational new drug design.
Stuart Orkin, M.D.Boston Children’s Hospital
Stuart H. Orkin is a stem cell biologist and researcher in pediatric hematology-oncology. He is the David G. Nathan Professor of Pediatrics at Harvard Medical School and is the chairman of pediatric oncology at the Dana–Farber/Harvard Cancer Center. Dr. Orkin’s research has focused on the genetic basis of blood disorders. He is a member of the National Academy of Sciences and the Institute of Medicine.
David Scadden, M.D.Massachusetts General Hospital
He is the Gerald and Darlene Jordan Professor of Medicine, Harvard Medical School, Co-Director, and co-founder, Harvard Stem Cell Institute. His laboratory focuses on the regulation of hematopoiesis by both hematopoietic cell autonomous and non-autonomous means, with particular emphasis on the hematopoietic stem cell niche and its role in normal and malignant disease.
Frederick J. Schoen, M.D., PH.D.Brigham and Women's Hospital
Dr. Schoen is Senior Pathologist at Brigham and Women’s Hospital, Professor of Pathology and Health Sciences and Technology, Harvard Medical School and Executive Vice Chairman, Department of Pathology, Brigham and Women’s Hospital. Dr. Schoen investigates medical device development and pathology, mechanical and tissue heart valve substitutes and tissue engineering of heart valves.
Gary Tearney, M.D., PH.D.Massachusetts General Hospital
Professor of Pathology, Harvard Medical School, and Associate Director, Wellman Center for Photomedicine. He has spent over 20 years developing and validating new imaging technologies to combat human disease, most notably optical coherence tomography (OCT) technology. He directs a laboratory responsible for first-in-human studies with pulmonary, coronary vessel, and esophageal OCT devices and he is currently the PI of approximately 10 clinical trials that investigate the clinical utility of these technologies.
Scott Weiss, M.D.Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School, Director of the Partners Health Care Center for Personalized Genetic Medicine (PCPGM), Associate Director of the Channing Division of Network Medicine and the co-leader of the Systems Genetics and Genomics research group at the Channing Division of Network Medicine, Department of Medicine, BWH. Dr. Weiss has authored or co-authored over 550 papers and co-written and co-edited four books, including a comprehensive textbook in respiratory genetics. He has been continuously funded by NHLBI for 38 years and was recently identified as part of the top 1% of biomedical researchers in terms of impact (Eur J Clin Investigation 2013 PMID: paperpal:24134636).
Burt Adelman, M.D.Various Biotech Boards
Executive Vice President of Dyax Corporation where he oversees the clinical/medical affairs and regulatory departments, in addition to technical operations, which includes manufacturing, quality assurance and quality control. He has experience and expertise in drug development and commercialization. His experience and expertise in drug development spans from discovery to development to commercial promotion and includes biologics and small molecules.
Carl Berke, PH.D.Partners Innovation Fund
Dr. Berke’s career has spanned over 25 years in the practice and management of innovation to bring new technologies from lab to market. As a bench scientist and R&D director, he worked at Polaroid Corporation and Hygeia Sciences in the development of photographic and clinical products for both consumer and professional markets. He served as a Partner at Integral/Analysis Group, a consulting firm, focusing on the management of innovation and growth strategy for clients in healthcare and consumer products. He has been an active private equity investor as a member of Angel Healthcare Investors LLC and is a founder of Mass Medical Angels and has served on the boards of Quosa, Kasalis, Combinent, Infobionic and the Sudanese Education Fund. Carl holds an AB degree from Cornell University and received his PhD in Organic Chemistry from the University of California at Berkeley.
Christopher H. Colecchi, M.P.H.Broadview Ventures
Christopher H. Colecchi is the Managing Director of Broadview Ventures, the philanthropic venture investing arm of the Paris-based Leducq Family Trust. Broadview’s mission is to accelerate the development of cures for cardiovascular diseases through investments in promising early stage companies. Chris’s responsibilities include leading a team that sources and assesses potential investments, develops the investment terms, and provides guidance to portfolio companies. Chris also coordinates the activities of Broadview’s Strategic Advisory Board, consisting of eminent cardiologists, scientists and world-class business and investment leaders. Broadview Ventures makes investments in both the U.S. and Europe from its Boston headquarters. To date, Broadview has invested in twenty cardiovascular technologies including therapeutics, devices, and diagnostics. Chris sits on the boards of directors as an observer on several of these companies.
Robert Farra, M.S.CeQur
Robert Farra is the CEO of CeQur Corp, a company developing a 3-day wearable insulin device for people with type 2 diabetes. Prior to CeQur, he was with Microchips Biotech, an MIT startup developing implantable drug delivery devices; there he held various roles including President and COO, CTO, and Vice President of R&D. He was instrumental in advancing the wireless drug delivery platform and in developing strategic partnerships with Teva and the Bill and Melinda Gates Foundation. Previously, he was Vice President of Engineering and Manufacturing for Abiomed leading all new product development, new product introduction and commercial manufacturing. Mr. Farra also held senior leadership positions at Accellent (now part of Greatbatch) and Arthur D. Little where he led new product development efforts as well as business development. Mr. Farra’s experience spans all aspects of transforming technologies into successful, commercial products, including: business development, fundraising, research, product development, intellectual property strategy, regulatory, and operations. He has numerous issued and pending patents. His product development experience includes sophisticated electro-mechanical and fluidic-based medical devices and combination products, drug delivery technologies, wirelessly programmable implants, implantable glucose sensors, ventricular assist devices, artificial hearts, intra-aortic balloons and pumps, minimally invasive laparoscopic, endoscopic, and interventional devices. Mr. Farra has an SMME from MIT.
Meredith Fisher, PH.D.Partners Innovation Fund
Meredith Fisher, PhD joins us from the private/family office of Bracebridge Capital where she was Director of Private Investments focusing on early stage biotech and medtech companies. Previously she was head of BD at Ginkgo BioWorks, a synthetic biology company founded at MIT. Prior to that role, she was Senior Director of Technology and BD at Enlight Biosciences, a venture creation firm founded by PureTech Ventures and partnered with seven major pharmaceutical companies. Meredith received a PhD from Harvard University in molecular microbiology, an MBA from the Sloan school at MIT and an AB from Mount Holyoke College.
Mark A. Goldberg, M.D.Various Biotech Boards
Dr. Mark Goldberg is a Clinical Associate Professor of Medicine at Harvard Medical School and currently holds appointments at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute. Dr. Goldberg is an officer at Synageva and previously was a member of the Board of Directors for private Synageva. Before joining the management team at Synageva, he served in various management capacities at Genzyme Corporation and was the Chairman of Genzyme’s Early Product Review Board. Additionally, he has been a member of the Board of Directors of Immunogen Corporation where he has served on the governance and nominating committee since November, 2011, and a member of the Board of Directors of Idera Pharmaceuticals.
Keith M. Gottesdiener, M.D.Rhythm Pharmaceuticals, Inc.
Keith Gottesdiener, MD, is Chief Executive Officer of Rhythm Pharmaceuticals, Inc., a Boston-based biotech company that specializes in the development of peptide therapeutics for the treatment of metabolic diseases. Dr. Gottesdiener brings great depth and breadth of experience in pharmaceutical development. Previously, he spent 16 years at Merck Research Laboratories, first leading early clinical development at Merck, then leading all late-stage clinical development efforts. Overall, he played a leading role or was directly responsible for the US approval of more than10 new drug applications and the successful submission of more than 200 investigational new drug applications. Dr. Gottesdiener received his BA from Harvard College and his MD from the University of Pennsylvania. He completed his residency in internal medicine and an infectious disease fellowship at the Brigham and Women’s Hospital of Harvard Medical School.
Phillip Thomas Gross Adage Capital Management
Phill has been an equity analyst and portfolio manager following the healthcare therapeutics and medical device industries for over 30 years. Phill is a Co-Founder, Managing Director and Healthcare Portfolio Manager at Adage Capital Management, L.P. Prior to founding Adage in 2001, Phill was the Healthcare Analyst, Equity Research Director and a Partner at the Harvard Management Company. Mr. Gross is on the Harvard Medical School Board of Fellows, the Dana-Farber Cancer Institute Board of Trustees, Founder and Treasurer of Strategic Grant Partners, and is on the University of Wisconsin Foundation Investment Committee.
Sepideh Hashemi, MSBoston Biomedical Associates
As a member of the Boston Biomedical Associates senior leadership team, Sepi’s responsibilities include strategic planning, oversight of growth practices, program management and organizational development. She brings a deep interest in catalyzing connections between disease insights, technology breakthroughs and patient care. Prior to joining Boston Biomedical Associates, Sepi held senior positions at Partners HealthCare Innovation as Market Sector Leader and in industry including Vice President in R&D and Clinical Sciences at Boston Scientific and COO at Digizyme Inc. During her 20 years at Boston Scientific, she was responsible for design and development of cardiovascular implants, oversight of cross functional product and technology programs as well as creation of the corporate due diligence process utilized for effective assessment and integration of acquired entities to achieve a diverse and profitable portfolio.
Jerry Karabelas, PH.D.Care Capital
Jerry is a partner at Care Capital in Princeton, NJ, a life sciences venture capital firm with $500 mm under management. Jerry was the founder of the Novartis BioVenture Fund. Previous to that he was CEO of the Novartis healthcare division, world wide, and the Executive VP and head of Global Pharmaceuticals at SmithKline Beecham. Jerry has been chairman of the board of a number of life science companies including Human Genome Sciences, Vanda Pharmaceuticals, Skye Pharma, NitroMed pharmaceuticals, and Polyphor Pharmaceuticals. Jerry has a PhD in pharmacokinetics from Mass College of Pharmacy and a BS in biochemistry from the University of NH. He was previously a member of Mass General’s Scientific Advisory Committee and an advisor to the Singapore government’s Bio-One Capital.
Jay Knowles, MBAPartners Innovation Fund
Jay is an experienced business development professional with more than 20 years in the industry and has guided multiple early stage companies through drug discovery and development. He has been President or CEO of venture and angel-backed companies, most recently as CEO, X-BODY Biosciences, an emerging biotech focused on generating antibodies against GPCRs and ion channels. Prior to this, he was Head, Platforms, Strategic Alliances for Novartis, where he led a team responsible for creating technology-based and drug discovery collaborations, forging a number of major strategic alliances with biotech companies. He has an MBA in Finance from Wharton Business School, an M.Sc. in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College. He is a Member of the Board of Directors at Aurigene and at X-BODY, and represents the fund as a board observer at RaNA Therapeutics.
Christopher K. Mirabelli, PH.D.Leap Therapeutics
President, DecImmune and Managing Director, HealthCare Ventures, Chief Executive Officer and Chairman of the Board of Directors of Leap Therapeutics (LPTX) since 2016. Dr. Mirabelli joined HealthCare Ventures in 2000 and is a Managing Director at the firm. Dr. Mirabelli was Chairman of the Board and Chief Executive Officer of LeukoSite, Inc. from 1993 through 1999, a company in which HealthCare Ventures was the lead investor. Dr. Mirabelli was also a co-founder of Isis Pharmaceuticals and served with SmithKline and French Laboratories R&D Division. Dr. Mirabelli received his doctorate in molecular pharmacology from Baylor College of Medicine.
Enrico Petrillo, M.D.Petrillo Capital
Enrico is a General Partner of CB Health Ventures LLC. He was the Managing Director of Excel Venture Management. Dr. Petrillo served as a Board Observer at Aventura HQ, Inc. He has been a Board Observer of SpringLeaf Therapeutics Inc., since July 2011. He serves as an Advisor of ShapeUp Inc. He also serves as an Advisor to the United States Department of Defense, Office of the Secretary and affiliated agencies. Dr. Petrillo has extensive experience as a venture investor, healthcare consultant, entrepreneur, and physician that has been instrumental in the success of CB Health Ventures (CBHV) and Excel Venture Management. He has been advising and building successful healthcare and IT companies for over 20 years. He was a Founding Partner of the Health Care Commercialization Group. Prior to CB Health Ventures, he was a Founding Partner of Fletcher Spaght, Inc., and served as its Senior Consultant from 1984 to 1996 and Head of Healthcare Commercialization from 1991 to 1996. Dr. Petrillo holds an undergraduate and an M.D. from Tufts University and completed an Internship, Residency, and Fellowship Training in General Internal Medicine at Mt. Auburn Hospital (Harvard Medical School).
Geoffrey Smith, J.D.Digitalis Ventures
Geoffrey W. Smith is the Managing Director of Mars Grand Challenge Ventures, the strategic venture capital arm of Mars, Inc. He is also a co-founder and general partner of Ascent Biomedical Ventures, a New York City-based venture capital firm focused on early-stage life sciences investments. Having been an active founder, manager, and investor in technology-based companies since 1995, he currently serves on the boards of directors of Azevan Pharmaceuticals, BackBeat Medical, Biomerix, Caliber Therapeutics, Coferon, TargAnox, and Vivasure Medical. Geoff is also a visiting scholar at Rockefeller University, where he founded and directs the university’s Science & Economics Program and is an adjunct faculty member at the RU Center for Clinical and Translational Science. He also is a member of the Scientific Advisory Board for Brigham & Women’s Hospital in Boston. Previously, he was the founding Director of the Mount Sinai Institute of Technology and a Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai. Geoff received a B.A. (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.
David P. White, M.D.
Dr. White graduated from Emory University Medical School and completed training in Internal Medicine and Pulmonary Disease at the University of Colorado Health Sciences Center. He has held a number of positions at various universities over his career and is currently a Professor of Medicine at the Harvard Medical School and works heavily with both Philips Respironics and Apnicure. Some of his major accomplishments include being President of the American Academy of Sleep Medicine, Chairing the Task Force to write the research plan addressing sleep and its disorders for the National Institutes of Health, and being the Editor-in-Chief of the Journal SLEEP. He was also on the test writing committees for the American Board of Internal Medicine for both Pulmonary Disease and Sleep Medicine. Finally, his principle research interest has been the pathophysiology of disorders of breathing during sleep about which he has published over 200 original papers.